Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferoxamine and Deferiprone in Thalassemia Major with Cardiac Disease
NCT00800761Phase 4Completed
- Sponsor
- Ospedale Microcitemico
- Start
- Dec 2001
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of deferiprone in iron overload cardiomyopathy (IOC) (2 arms), sponsored by Ospedale Microcitemico. Primary endpoint: Prevalence of cardiovascular deaths and hospitalisations for cardiovascular disease at 42 months. Started Dec 2001; status: completed.
02
Drugs
deferiprone
03
Conditions
iron overload cardiomyopathy (IOC)
Beyond the preview
Go deeper on NCT00800761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00800761.